Landmark Phase III Win for Personalized mRNA Cancer Therapy

A PERSONALIZED mRNA cancer therapy improved recurrence and metastasis outcomes after melanoma surgery in a Phase III trial.

The randomized INTerpath-001 trial evaluated intismeran autogene combined with pembrolizumab as adjuvant therapy for patients with completely resected Stage IIB, IIC, III, or IV cutaneous melanoma. At a prespecified interim analysis, the combination produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared with pembrolizumab alone.

These topline findings represent the first positive Phase III results reported for an individualized neoantigen therapy and an mRNA-based cancer treatment. However, numerical efficacy estimates, confidence intervals, follow-up duration, and detailed subgroup findings were not disclosed. The study will continue to assess overall survival and other secondary outcomes.

Phase III Trial Design and Treatment Schedule

INTerpath-001 enrolled 1,137 patients following complete surgical resection. Participants who had not previously received systemic therapy were randomized 2:1 to combination treatment or pembrolizumab with placebo.

Patients assigned to the experimental group received intismeran at 1 mg every 3 weeks for up to nine doses. Pembrolizumab was administered at 400 mg every 6 weeks for up to nine cycles. Treatment continued for approximately 1 year, until recurrence or unacceptable toxicity, or for a maximum of approximately 56 weeks.

Recurrence-free survival, the primary endpoint, was defined as the time from randomization to local, locoregional, regional, or distant recurrence, or death from any cause. Secondary endpoints include distant metastasis-free survival, overall survival, safety, tolerability, and quality of life.

A Personalized Approach to Adjuvant Melanoma Treatment

Intismeran is created from an individual patient’s tumor sample. The investigational therapy contains synthetic messenger RNA encoding up to 34 neoantigens selected from the tumor’s unique mutational profile. These sequences are intended to activate tumor-specific T-cell responses.

Combining this individualized approach with anti-PD-1 therapy may strengthen immune recognition while limiting tumor-mediated immune suppression. The safety profiles were consistent with earlier studies of the combination, with no new safety signals identified.

The findings are promising for patients who remain vulnerable to recurrence after apparently complete resection. Nevertheless, the personalized mRNA cancer therapy remains investigational. Detailed efficacy and safety data, overall survival results, presentation at a medical meeting, and regulatory review will be necessary before its potential clinical role can be fully established.

Reference
Merck and Moderna. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma. 19 August 2026. Available at: https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/. Last accessed: 21 August 2026.

Featured Image: LIGHTFIELD STUDIOS on Adobe Stock.